Talphera (TLPH) Non Operating Income (2010 - 2026)
Talphera's (TLPH) quarterly Non Operating Income came in at $1.4 million in Q1 2026, up 456.8% year-on-year from $250000.0 in Q1 2025, and up 536.36% quarter-over-quarter from -$319000.0 in Q4 2025.
Talphera (TLPH) Non Operating Income (2010 - 2026) Analysis & Trends
Talphera's Non Operating Income history runs 17 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- On a quarterly basis, Non Operating Income rose 456.8% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $263000.0, a 88.13% decrease from a year earlier, with the FY2025 full-year figure at -$879000.0, down 139.1% from the prior year.
- Non Operating Income improved to $1.4 million in Q1 2026 per TLPH's latest filing, from -$319000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $84.3 million in Q2 2022 and bottomed at -$1.0 million in Q3 2025.
- The 5-year median for Non Operating Income is $266500.0 (2024), against an average of $5.5 million.
- Across the five-year window, Non Operating Income jumped 49765.68% in 2022 and plunged 356.06% in 2025, its largest moves.
- Year by year, Non Operating Income stood at -$51000.0 in 2022, then slumped by 345.1% to -$227000.0 in 2023, then surged by 596.04% to $1.1 million in 2024, then slumped by 128.33% to -$319000.0 in 2025, then jumped by 536.36% to $1.4 million in 2026.
- Per Business Quant, the three latest TLPH Non Operating Income figures stand at $1.4 million (Q1 2026), -$319000.0 (Q4 2025), and -$1.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | -319,000.00 |
| Sep 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | 204,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 396,000.00 |
| Jun 30, 2024 | 443,000.00 |
| Mar 31, 2024 | 283,000.00 |
| Dec 31, 2023 | -227,000.00 |
| Sep 30, 2023 | 1.89 Mn |
| Jun 30, 2023 | -456,000.00 |
| Dec 31, 2022 | -51,000.00 |
| Sep 30, 2022 | -105,000.00 |
| Jun 30, 2022 | 84.27 Mn |
| Mar 31, 2022 | 321,000.00 |
| Dec 31, 2021 | 258,000.00 |
| Sep 30, 2021 | 258,000.00 |
| Jun 30, 2021 | 169,000.00 |
| Mar 31, 2021 | 186,000.00 |